Court rules companies can't import Gilead medications from overseas in blow to AFP health programs

A U.S. appeals court ruled that companies operating alternative funding programs cannot legally import Gilead Sciences medications from overseas sources. The decision upheld restrictions on importing the pharmaceutical manufacturer's drugs into the United States. Alternative funding programs have provided lower-cost medications to patients, particularly those with limited insurance coverage.

Next story